Patents by Inventor JIH-HENG LI

JIH-HENG LI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-human urothelial carcinoma of supercritical carbon dioxide extract of , and the preparation process and uses
    Patent number: 8669377
    Abstract: What is disclosed in the invention is a preparation method of a supercritical Cinnamomum subavenium extract, which is made from the material, the dried stem of C. subavenium. The extract is obtained by extracting C. subavenium which is pulverized as particles with supercritical carbon dioxide fluid. The C. subavenium extract or its active ingredient, subamolide A, can be used to inhibit the growth of human urothelial carcinoma cell lines. In addition, the C. subavenium extract (or subamolide A) is able to synergistically inhibit the growth of human urothelial carcinoma cell lines with cisplatin (CDDP) or gemcitabine (Gem). Therefore, the C. subavenium extract (or subamolide A) can be an anticancer drug alone, or forms a pharmaceutical composition with CDDP (or Gem) to treat with cancers in respect of urinary system.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: March 11, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Jih-Heng Li, A-Mei Huang, Chung-Yi Chen, Pei-Jung Lien, Chiung-Hui Liu
  • ANTI-HUMAN UROTHELIAL CARCINOMA OF SUPERCRITICAL CARBON DIOXIDE EXTRACT OF CINNAMOMUM SUBAVENIUM, AND THE PREPARATION PROCESS AND USES
    Publication number: 20130122110
    Abstract: What is disclosed in the invention is a preparation method of a supercritical Cinnamomum subavenium extract, which is made from the material, the dried stem of C. subavenium. The extract is obtained by extracting C. subavenium which is pulverized as particles with supercritical carbon dioxide fluid. The C. subavenium extract or its active ingredient, subamolide A, can be used to inhibit the growth of human urothelial carcinoma cell lines. In addition, the C. subavenium extract (or subamolide A) is able to synergistically inhibit the growth of human urothelial carcinoma cell lines with cisplatin (CDDP) or gemcitabine (Gem). Therefore, the C. subavenium extract (or subamolide A) can be an anticancer drug alone, or forms a pharmaceutical composition with CDDP (or Gem) to treat with cancers in respect of urinary system.
    Type: Application
    Filed: March 21, 2012
    Publication date: May 16, 2013
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: JIH-HENG LI, A-MEI HUANG, CHUNG-YI CHEN, PEI-JUNG LIEN, CHIUNG-HUI LIU